Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Consulting agrmnt
Inv. presentation
Quarterly results
Asset acq. complete
Director departure
CC transcript
Asset disposition
Acq. announced
Protagenic Therapeutics, Inc.\new (PTIX) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/13/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
05/15/2023 10-Q Quarterly Report for the period ended March 31, 2023
04/17/2023 10-K/A Annual Report for the period ended December 31, 2022 [amend]
03/31/2023 10-K Annual Report for the period ended December 31, 2022
03/22/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and ...
Docs: "CERTIFICATE OF AMENDMENT OF THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF PROTAGENIC THERAPEUTICS, INC. Protagenic Therapeutics, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware , hereby certifies as follows: 1. That the Board of Directors duly adopted resolutions approving the amendment of the Certificate of Incorporation of this corporation to effect a reverse stock split in the range of 1-for-2 to 1-for-4, with the exact ratio to be set within that range at the discretion of our board of directors without further approval or authorization of our stockholders and with our board of directors able to elect to abandon such proposed amendment and not effect the reverse split authorized by sto...",
"Protagenic Therapeutics to Effect 1-for-4 Reverse Stock Split"
02/14/2023 SC 13G/A ARMISTICE CAPITAL, LLC reports a 5.3% stake in PROTAGENIC THERAPEUTICS, INC.
11/28/2022 8-K Submission of Matters to a Vote of Security Holders, Other Events  Interactive Data
11/14/2022 10-Q Quarterly Report for the period ended September 30, 2022
09/02/2022 8-K Other Events  Interactive Data
08/11/2022 10-Q Quarterly Report for the period ended June 30, 2022
06/29/2022 8-K Quarterly results
05/18/2022 4 Arrow Alexander K. (CFO) has filed a Form 4 on Protagenic Therapeutics, Inc.\new
Txns: Bought 23,000 shares @ $0.71, valued at $16.3k
Bought 8,000 shares @ $0.72, valued at $5.8k
05/13/2022 10-Q Quarterly Report for the period ended March 31, 2022
04/07/2022 10-K Annual Report for the period ended December 31, 2021
03/31/2022 NT 10-K Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405:
03/08/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
02/14/2022 SC 13G ARMISTICE CAPITAL, LLC reports a 5.4% stake in Protagenic Therapeutics, Inc.
02/04/2022 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
10/05/2021 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
10/01/2021 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders...
09/20/2021 EFFECT Form EFFECT - Notice of Effectiveness:
09/10/2021 S-3/A Form S-3/A - Registration statement under Securities Act of 1933: [Amend]
09/08/2021 DEF 14A Form DEF 14A - Other definitive proxy statements:
08/18/2021 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Protagenic Therapeutics Announces Second Quarter 2021 Results and Provides Business Update"
08/16/2021 10-Q Quarterly Report for the period ended June 30, 2021
08/13/2021 S-3 Form S-3 - Registration statement under Securities Act of 1933:
07/23/2021 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Docs: "Protagenic Therapeutics Updates Timeline for Commencement of Patient Enrollment for PT00114 Clinical Trial"
07/02/2021 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "At Market Issuance Sales Agreement, by and between Protagenic Therapeutics, Inc., B. Riley Securities, Inc. and EF Hutton, division of Benchmark Investments, LLC",
"Opinion of Duane Morris LLP"
07/02/2021 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
06/24/2021 EFFECT Form EFFECT - Notice of Effectiveness:
06/21/2021 S-3/A Form S-3/A - Registration statement under Securities Act of 1933: [Amend]
06/04/2021 S-3 Form S-3 - Registration statement under Securities Act of 1933:
06/03/2021 4 Arrow Alexander K. (CFO) has filed a Form 4 on Protagenic Therapeutics, Inc.\new
Txns: Bought 100 options to buy @ $4.98, valued at $498
Bought 16,900 options to buy @ $4.98, valued at $84.2k
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy